Shark nanobodies identify pan-coronavirus spike sites of vulnerability fortherapeutic intervention

Active Grant Awarded

Award ID
R01AI192916
Recipient
Awarding agency
Obligated
$896,045

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 11% complete
Place of performance
Baltimore, MD 21201, USA

Award details come from USAspending.gov.

About this award

The U.S. Department of Health and Human Services, through the National Institutes of Health's National Institute of Allergy and Infectious Diseases, awarded $896,045 to the University of Maryland, Baltimore on May 6, 2026, under Grant R01AI192916 in the Allergy and Infectious Diseases Research program (CFDA 93.855). The project develops broadly protective immunotherapeutic molecules for use if a coronavirus spillover with pandemic potential occurs. Researchers immunize nurse sharks sequentially with heterologous coronavirus spike proteins, priming with SARS-CoV-2 and recalling with SARS-CoV-1, MERS-CoV, or 229E immunogens, then interrogate the resulting VNAR nanobody repertoires for broadly conserved neutralizing epitopes. Isolated nanobodies are produced recombinantly and evaluated through binding, affinity, and competition mapping, pseudovirus and live-virus neutralization, and in vivo protection studies in animal models that mimic high-risk human populations. The project anticipates nanobodies targeting pan-sarbecovirus, pan-merbecovirus, and pan-alphacoronavirus epitopes. The period of performance runs from the May 6, 2026 award date to an ultimate completion date of April 30, 2031, with work performed in Baltimore, Maryland 21201. Two sub-awards pass funding through the recipient to Trudeau Institute Inc. (dated July 29, 2026) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (dated June 25, 2026).

Description

Abstract
Coronaviruses (COVS) cause significant disease in humans and have the propensity to shift between zoonotic reservoirs and into human populations, making them a continual global health threat. To date, seven different strains of COVS have been found to infect humans, of which sars-COV-1, sars-COV-2, and mers-COV (all betacoronaviruses) have previously caused pandemics and still pose severe threats to global health. Worldwide efforts during the covid-19 pandemic (caused by sars-COV-2) led to the rapid development of vaccines and monoclonal antibody therapies (MABS) that showed great effectiveness in reducing disease severity and preventing death in vulnerable populations. However, viral variants of concern (VOC) have continued to emerge, many of which have escaped the previously approved MABS, while the pandemic potential of new coronavirus spillover events remains high. Thus, the overall aim of this project is the development of broadly-protective immunotherapeutic molecules that can be easily deployed should a COV spillover of pandemic potential occur. To achieve this, we will interrogate vnar nanobody repertoires derived from nurse sharks that have received sequential immunizations with heterologous COV spfns, i.e., primed with sars-COV-2 spfn, then recalled with sars-COV-1 spfn, mers-COV, or 229E spfn immunogens, to identify broadly conserved, neutralizing epitopes. Isolated nanobodies will be produced in recombinant form and evaluated for function and specificity using binding, affinity, and competition mapping assays, followed by pseudovirus and live-viral neutralization, and in vivo protection studies with animal models that mimic high-risk human populations. Based upon our preliminary studies we anticipate that we will find vnar nanobodies that can target (I) pan-sarbecovirus epitopes, (II) pan-merbecovirus epitopes, and (III) pan-alphacoronavirus epitopes. Using X-RAY crystallography and cryo-EM imaging we will determine the binding epitope of each vnar. This atomic-level information will allow a complete understanding of the molecular recognition of antibody specificity and cross-reactivity, as exposed by the unique recognition capabilities of shark vnars. Using a structure-guided approach the most potent nanobodies will be combined to create multi-valent molecules with prophylactic and therapeutic activity. These will be tested in vivo with administration routes expanded to explore intranasal administration for increased efficacy and ease-of-use in future situations of pandemic potential.

Subawards

Subrecipient Amount Awarded
Trudeau Institute Inc. Shark nanobodies identify pan-coronavirus spike sites of vulnerability for therapeutic intervention. $201,849
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. $354,817

Quick answers

Who received award R01AI192916?

R01AI192916 was awarded to University Of Maryland, Baltimore by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 6, 2026.

How much is award R01AI192916 worth?

$896,045 has been obligated on R01AI192916.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award